Literature DB >> 12048256

Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486.

Zheng Liu1, Didier Auboeuf, Jiemin Wong, J Don Chen, Sophia Y Tsai, Ming-Jer Tsai, Bert W O'Malley.   

Abstract

Selective receptor modulators, such as the antiprogestin RU486, are known to exhibit partial agonist activities in a cell-type-dependent manner. Employing an in vitro chromatin transcription system that recapitulates progesterone receptor (PR)-mediated transcription in vivo, we have investigated the molecular basis by which the antiprogestin RU486 regulates transcription in a cell-type-specific manner. We have compared the effects of RU486 on PR-dependent transcription in vitro using T47D and HeLa cell nuclear extracts. RU486 exhibits a differential ability to activate transcription within these two cell types. The differential effect on transcription correlates with different ratios of endogenous coactivators/corepressors in these cells. Unlike agonist-bound PR that interacts only with coactivators such as steroid receptor coactivator-1 (SRC-1), RU486-bound PR binds to both coactivator SRC-1 and corepressor silencing mediator for retinoid and thyroid hormone receptor (SMRT) in vitro. Both SRC-1 and SMRT have the capacity to modulate RU486-dependent activity. Moreover, a change in the relative levels of SRC-1 and SMRT contained in our chromatin transcription system modulates agonist/antagonist effects of RU486 on transcription by PR. Our data indicate that the ability of RU486 to activate transcription is modulated by the ratio of coactivators to corepressors and substantiate the important roles of coregulators in the regulation of steroid receptor mediated transactivation in response to selective receptor modulators.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12048256      PMCID: PMC122999          DOI: 10.1073/pnas.122225699

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  The coregulator exchange in transcriptional functions of nuclear receptors.

Authors:  C K Glass; M G Rosenfeld
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

2.  Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II).

Authors:  N H Ing; J M Beekman; S Y Tsai; M J Tsai; B W O'Malley
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

3.  Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells.

Authors:  L Klein-Hitpass; A C Cato; D Henderson; G U Ryffel
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

Review 4.  The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?

Authors:  K B Horwitz
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

5.  The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor.

Authors:  E Vegeto; G F Allan; W T Schrader; M J Tsai; D P McDonnell; B W O'Malley
Journal:  Cell       Date:  1992-05-15       Impact factor: 41.582

6.  The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific.

Authors:  M T Bocquel; V Kumar; C Stricker; P Chambon; H Gronemeyer
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

7.  Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and receptor-dependent cell-free transcription of chromatin.

Authors:  Z Liu; J Wong; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

8.  Molecular determinants for the tissue specificity of SERMs.

Authors:  Yongfeng Shang; Myles Brown
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

9.  A single amino acid that determines the sensitivity of progesterone receptors to RU486.

Authors:  B Benhamou; T Garcia; T Lerouge; A Vergezac; D Gofflo; C Bigogne; P Chambon; H Gronemeyer
Journal:  Science       Date:  1992-01-10       Impact factor: 47.728

10.  Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor.

Authors:  M E Meyer; A Pornon; J W Ji; M T Bocquel; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  34 in total

1.  Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.

Authors:  Victoria Wargon; Marina Riggio; Sebastián Giulianelli; Gonzalo R Sequeira; Paola Rojas; María May; María L Polo; María A Gorostiaga; Britta Jacobsen; Alfredo Molinolo; Virginia Novaro; Claudia Lanari
Journal:  Int J Cancer       Date:  2014-11-12       Impact factor: 7.396

2.  p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization.

Authors:  Junaid A Khan; Larbi Amazit; Catherine Bellance; Anne Guiochon-Mantel; Marc Lombès; Hugues Loosfelt
Journal:  Mol Endocrinol       Date:  2011-08-04

3.  Structure, energetics, and dynamics of binding coactivator peptide to the human retinoid X receptor α ligand binding domain complex with 9-cis-retinoic acid.

Authors:  Gang Xia; LeeAnn J Boerma; Bryan D Cox; Cheng Qiu; Sebyung Kang; Craig D Smith; Matthew B Renfrow; Donald D Muccio
Journal:  Biochemistry       Date:  2010-12-08       Impact factor: 3.162

4.  Sex differences in epigenetic mechanisms may underlie risk and resilience for mental health disorders.

Authors:  Heather M Jessen; Anthony P Auger
Journal:  Epigenetics       Date:  2011-07-01       Impact factor: 4.528

Review 5.  New aspects of progesterone interactions with the actin cytoskeleton and neurosteroidogenesis in the cerebellum and the neuronal growth cone.

Authors:  Lisa Wessel; Laura Olbrich; Beate Brand-Saberi; Carsten Theiss
Journal:  J Histochem Cytochem       Date:  2014-08-20       Impact factor: 2.479

Review 6.  Development of selective androgen receptor modulators (SARMs).

Authors:  Ramesh Narayanan; Christopher C Coss; James T Dalton
Journal:  Mol Cell Endocrinol       Date:  2017-06-15       Impact factor: 4.102

Review 7.  Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy.

Authors:  Amber B Johnson; Bert W O'Malley
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

8.  Ligand-specific dynamics of the progesterone receptor in living cells and during chromatin remodeling in vitro.

Authors:  Geetha V Rayasam; Cem Elbi; Dawn A Walker; Ronald Wolford; Terace M Fletcher; Dean P Edwards; Gordon L Hager
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.

Authors:  Suzanne E Wardell; Ramesh Narayanan; Nancy L Weigel; Dean P Edwards
Journal:  Mol Endocrinol       Date:  2009-12-11

10.  Rapid effect of GNRH1 on follicle-stimulating hormone beta gene expression in LbetaT2 mouse pituitary cells requires the progesterone receptor.

Authors:  Beum-Soo An; Song Ling Poon; Wai-Kin So; Geoffrey L Hammond; Peter C K Leung
Journal:  Biol Reprod       Date:  2009-04-08       Impact factor: 4.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.